PUMA2A is a PUMA BH3-only peptide. PUMA2A can be used as a negative control in Cytochrome C release assays and BH3 profiling. PUMA2A can be used in the research of chronic myeloid leukemia [1] [2] [3] [4].
In Vitro, PUMA-2A (1-100 μM; 2 h) does not induce significant mitochondrial membrane potential loss in K562 CML cells[2].
References:
[1]. Dai J, et al. Intracellular BH3 Profiling Reveals Shifts in Antiapoptotic Dependency in Human B Cell Maturation and Mitogen-Stimulated Proliferation. J Immunol. 2018 Mar 1;200(5):1727-1736.
[2]. Lucas CM, et al. High CIP2A levels correlate with an antiapoptotic phenotype that can be overcome by targeting BCL-XL in chronic myeloid leukemia. Leukemia. 2016;30(6):1273-1281.
[3]. Butterworth M, et al. BH3 profiling and a toolkit of BH3-mimetic drugs predict anti-apoptotic dependence of cancer cells. Br J Cancer. 2016;114(6):638-641.
[4]. Alhuthali HM, et al. The natural alkaloid Jerantinine B has activity in acute myeloid leukemia cells through a mechanism involving c-Jun. BMC Cancer. 2020;20(1):629. Published 2020 Jul 7.
In Vitro, PUMA-2A (1-100 μM; 2 h) does not induce significant mitochondrial membrane potential loss in K562 CML cells[2].
References:
[1]. Dai J, et al. Intracellular BH3 Profiling Reveals Shifts in Antiapoptotic Dependency in Human B Cell Maturation and Mitogen-Stimulated Proliferation. J Immunol. 2018 Mar 1;200(5):1727-1736.
[2]. Lucas CM, et al. High CIP2A levels correlate with an antiapoptotic phenotype that can be overcome by targeting BCL-XL in chronic myeloid leukemia. Leukemia. 2016;30(6):1273-1281.
[3]. Butterworth M, et al. BH3 profiling and a toolkit of BH3-mimetic drugs predict anti-apoptotic dependence of cancer cells. Br J Cancer. 2016;114(6):638-641.
[4]. Alhuthali HM, et al. The natural alkaloid Jerantinine B has activity in acute myeloid leukemia cells through a mechanism involving c-Jun. BMC Cancer. 2020;20(1):629. Published 2020 Jul 7.